ArticlePharmacoEconomics - open2020
Ticagrelor Removal by CytoSorb
Article in PharmacoEconomics - open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Development, Validation, and Application of an HPLC Method Combined with an In Vitro Model for the Determination of Antibiotic Binding to the Haemoadsorber CytoSorbMolecules (Basel, Switzerland) · 2026Article
- Impact of CytoSorb Hemoadsorption Therapy on Cost-Effectiveness and Length of Stay in Critical Care Patients: A Preliminary Study from a Swiss High-Volume Center.Healthcare (Basel, Switzerland) · 2026Article
- Antibiotics and Other Drugs Removal by the CytoSorbAntibiotics (Basel, Switzerland) · 2026Review
- From critical care to organ preservation: the potential role of hemadsorption in transplantation-a narrative review.Hepatobiliary surgery and nutrition · 2025Review
- Extracorporeal Cytokine Adsorption in Sepsis: Current Evidence and Future Perspectives.Biomedicines · 2025Review
- Effective Apixaban removal using hemoadsorption during emergent open-heart surgery: a case report and narrative literature review.Journal of cardiothoracic surgery · 2024Review
- Cost-Effectiveness and Budget Impact of a Novel Antithrombotic Drug Removal System to Reduce Bleeding Risk in Patients on Preoperative Ticagrelor Undergoing Cardiac Surgery.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Article
- The use of CytoSorb® in a prasugrel-loaded patient undergoing emergent coronary artery bypass graft surgery.Clinical case reports · 2023Article
- StandardizedFrontiers in cardiovascular medicine · 2023Article
- Removal of Apixaban during Emergency Cardiac Surgery Using Hemoadsorption with a Porous Polymer Bead Sorbent.Journal of clinical medicine · 2022Article
- Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery-a systematic review.Journal of thoracic disease · 2022Review
- Application of Adsorptive Blood Purification Techniques during Cardiopulmonary Bypass in Cardiac Surgery.Oxidative medicine and cellular longevity · 2022Review
- Therapeutic Modulation of the Host Defense by Hemoadsorption with CytoSorbInternational journal of molecular sciences · 2021Article
- Hemoadsorption during Cardiopulmonary Bypass in Patients with Endocarditis Undergoing Valve Surgery: A Retrospective Single-Center Study.Journal of clinical medicine · 2021Article
- Reducing antithrombotic-related bleeding risk in urgent and emergency cardiac surgery.The British journal of cardiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAcute coronary syndrome patients receiving dual antiplatelet therapy who need emergent or urgent cardiac surgery are at high risk of major bleeding, which can impair postoperative outcomes. CytoSorb
objectiveThe aim of this study was to evaluate the cost utility of intraoperative removal of ticagrelor using CytoSorb versus usual care among patients requiring emergent or urgent cardiac surgery in the UK.
methodsA de novo decision analytic model, based on current treatment pathways, was developed to estimate the short- and long-term costs and outcomes. Results from randomised clinical trials and national standard sources such as National Health Service (NHS) reference costs were used to inform the model. Costs were estimated from the NHS and Personal Social Services perspective. Deterministic and probabilistic sensitivity analyses (PSAs) explored the uncertainty surrounding the input parameters.
resultsIn emergent cardiac surgery, intraoperative removal of ticagrelor using CytoSorb was less costly (£12,933 vs. £16,874) and more effective (0.06201vs. 0.06091 quality-adjusted life-years) than cardiac surgery without physiologic clearance of ticagrelor over a 30-day time horizon. For urgent cardiac surgery, the use of CytoSorb was less costly than any of the three comparators-delaying surgery for natural washout without adjunctive therapy, adjunctive therapy with short-acting antiplatelet agents, or adjunctive therapy with low-molecular-weight heparin. Results from the PSAs showed that CytoSorb has a high probability of being cost saving (99% in emergent cardiac surgery and 53-77% in urgent cardiac surgery, depending on the comparators). Cost savings derive from fewer transfusions of blood products and re-thoracotomies, and shorter stay in the hospital/intensive care unit.
conclusionsThe implementation of CytoSorb as an intraoperative intervention for patients receiving ticagrelor undergoing emergent or urgent cardiac surgery is a cost-saving strategy, yielding improvement in perioperative and postoperative outcomes and decreased health resource use.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.